Drug Profile
TM 29
Alternative Names: TCAR monoclonal TM 29Latest Information Update: 10 Aug 2000
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Crohn's disease
Most Recent Events
- 10 Aug 2000 Discontinued-Preclinical for Autoimmune disorders in Sweden (Unknown route)
- 10 Aug 2000 Discontinued-Preclinical for Autoimmune disorders in USA (Unknown route)
- 10 Aug 2000 Discontinued-Preclinical for Cancer in Sweden (Unknown route)